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ABSTRACT
Idiopathic pulmonary fibrosis (IPF) is a progressive disease that usually affects 
elderly people. It has a poor prognosis and there are limited therapies. Since epigenetic 
alterations are associated with IPF, histone deacetylase (HDAC) inhibitors offer a 
novel therapeutic strategy to address the unmet medical need. This study investigated 
the potential of romidepsin, an FDA-approved HDAC inhibitor, as an anti-fibrotic 
treatment and evaluated biomarkers of target engagement that may have utility in 
future clinical trials. The anti-fibrotic effects of romidepsin were evaluated both in 
vitro and in vivo together with any harmful effect on alveolar type II cells (ATII). 
Bronchoalveolar lavage fluid (BALF) from IPF or control donors was analyzed for the 
presence of lysyl oxidase (LOX). In parallel with an increase in histone acetylation, 
romidepsin potently inhibited fibroblast proliferation, myofibroblast differentiation 
and LOX expression. ATII cell numbers and their lamellar bodies were unaffected. 
In vivo, romidepsin inhibited bleomycin-induced pulmonary fibrosis in association 
with suppression of LOX expression. LOX was significantly elevated in BALF of IPF 
patients compared to controls. These data show the anti-fibrotic effects of romidepsin, 
supporting its potential use as novel treatment for IPF with LOX as a companion 
biomarker for evaluation of early on-target effects.
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INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a progressive 
disease, where the median survival has been reported as 
2-5 years from diagnosis. This disease is more common 
in middle-aged adults and its incidence increases with age 
suggesting that IPF may be a consequence of accelerated 
aging of the lung [1, 2]. In addition to lung transplantation, 
two new drugs, pirfenidone (Esbriet®) and nintedanib 
(Ofev®) have recently been approved for IPF treatment. 
Pirfenidone reduces the risk of disease progression [3, 4], 
while nintedanib reduces the annual decline in forced vital 
capacity by approximately 50% [5], but both are associated 
with undesirable side effects [4, 5]. To date, no therapy has 
successfully halted, much less reversed, the decline in lung 
function that is a hallmark of IPF. Therefore, additional 
drugs that may be used as sole agents or in combination 
with existing therapies are urgently required to improve 
patient outcomes.
IPF is characterized by multi-focal destruction of 
the lung architecture, with accumulation of highly active 
fibroblasts and myofibroblasts that produce excessive 
amounts of extracellular matrix (ECM) [6] resulting 
in impaired gas exchange. Studies in a range of fibrotic 
diseases including IPF have shown that fibroblasts from 
the affected organ display aberrations in nearly every 
aspect of the fibroproliferative/fibrogenic response [7, 8]. 
Reasons for such widespread functional alterations have 
not been established in detail. However, while the cause(s) 
of IPF are unknown, the disease has a series of biological 
abnormalities (genetic and epigenetic alterations) and risk 
factors (aging, smoking and environmental exposures) 
in common with cancer [9]. Specifically, epigenetic 
mechanisms have been proposed to account for the 
aggressive phenotype of fibrotic fibroblasts [10-12]. 
Most recently altered expression of histone deacetylases 
(HDACs) has been reported in IPF lung tissue, especially 
in fibroblastic foci, the regions of active fibroproliferation 
[12]. Thus epigenetic alterations, presumably occurring 
in response to environmental exposures and/or aging, 
may be the missing link that predisposes the pulmonary 
fibroblasts for gene expression changes associated with the 
development of IPF. 
Because of HDAC dysregulation in cancer, 
inhibitors of these enzymes have been developed, and 
shown to possess potent anti-proliferative activities 
towards cancer cells [13]. Several studies have 
demonstrated anti-fibrotic properties for HDAC inhibitors 
such as trichostatin A (TSA), vorinostat (SAHA) and 
panobinostat (LBH589) [12, 14-16] which inhibit multiple 
classes of HDACs. However, we have shown that selective 
inhibition of class I HDACs using spiruchostatin A (SpA) 
was sufficient to reduce the proliferation of IPF fibroblasts 
and suppressed expression of interstitial collagen in 
vitro [17]. Romidepsin is also a class I selective HDAC 
inhibitor [18, 19], but it is already FDA-approved for 
treatment of cutaneous T-cell lymphoma (CTCL) with 
no reported pulmonary toxicity [20, 21]. Romidepsin has 
also been used in phase II trials in lung cancer [22, 23], 
demonstrating selectivity towards tumor cells, crucially, 
appearing relatively harmless to normal lung epithelial 
cells [22]. Taken together, these findings strongly suggest 
that romidepsin merits further investigation as a potential 
therapy for the treatment of fibrosis.
Herein, we investigated the antifibrotic effects of 
romidepsin in vitro and in vivo. Since evaluation of novel 
IPF therapies poses considerable challenges in selecting 
outcome measures that allow assessment of clinically 
meaningful effects, we also investigated whether the 
extracellular enzyme, lysyl oxidase (LOX) has potential 
to act as a biomarker for evaluation of the anti-fibrotic 
effects of romidepsin. LOX post-translationally modifies 
collagens and elastin to enable covalent cross-linking 
and is induced by the profibrotic mediator, transforming 
growth factor beta (TGF-β) [24, 25]. A strong association 
between organ fibrosis and increased LOX activity has 
been observed [26-29]. We therefore explored the effect of 
romidepsin on LOX expression in vitro, in vivo and in IPF 
bronchoalveolar fluid (BALF). This work has previously 
been presented in abstract form [30-34].
RESULTS
Romidepsin induces histone H3 acetylation
As romidepsin is a histone deacetylase inhibitor, we 
first assessed histone acetylation in fibroblasts isolated 
by outgrowth from IPF lung tissue explants. As shown in 
Figure 1A, romidepsin caused a dose dependent increase 
in histone H3 acetylation; semi-quantitative analysis 
demonstrated a doubling in H3 acetylation by 144 hours 
after treatment with 1nM romidepsin and, with 10nM 
romidepsin acetylation had increased 4-fold compared 
to control (Figure 1B). Time-course experiments showed 
that acetylation was evident after 48h and continued to 
increase in a time dependent manner. Thus, at 10nM 
romidepsin, acetylation had doubled by 48h and almost 
doubled again by 72h. Beyond this time, the acetylation 
plateaued (Figure 1C). TGF-β
1
 appeared to have little 
effect on the degree of acetylation caused by romidepsin.
Romidepsin diminishes fibroblast proliferation 
and induces cell cycle arrest via CDKN1A 
expression
Fibroblasts from IPF lung tissue were cultured in 
serum-containing medium to optimize their proliferative 
potential and treated in the absence or presence of TGF-β
1
, 
which was used to mimic a pro-fibrotic environment. 
Treatment with romidepsin over 7 days had an inhibitory 
Oncotarget3www.impactjournals.com/oncotarget
effect on fibroblast proliferation: the IC
50
 for romidepsin 
at 144h was 0.5nM in the absence of TGF-β
1
 and 0.6nM 
in the presence of TGF-β
1 
(Figure 2A). These IC
50
 values 
for IPF fibroblasts were slightly lower than those of 
fibroblasts from normal lung parenchyma when treated in 
an identical manner (Figure 2B). 
Several studies, including one in IPF fibroblasts, 
have suggested that suppression of proliferation by HDAC 
inhibitors is due to induction of cell cycle arrest involving 
up-regulation of cell-cycle inhibitors such as CDKN1A 
(p21waf1) [17, 35, 36]. We therefore evaluated the effects 
of romidepsin on CDKN1A expression in IPF fibroblasts. 
At 48h, increased expression was evident at doses of 
romidepsin as low as 0.1nM. In the absence of TGF-β
1
, a 
doubling of expression was seen at 1nM romidepsin, while 
at 5 and 10nM, a 3-fold increase in CDKN1A expression 
was seen. In the presence of TGF-β
1
, induction of 
CDKN1A was observed at baseline and there was a 3-fold 
increase at 1nM romidepsin (Figure 2C). Romidepsin 
treatment also induced CDKN1A in normal control 
fibroblasts, but to a lesser extent than those cultured from 
IPF tissue (163±8% stimulation vs. 232±26% at 1nM 
romidepsin). Cell cycle analysis using FACS confirmed 
that romidepsin treatment caused fibroblasts to undergo 
G1 arrest with a significant reduction in the number of 
cells in S phase at 1nM and 5nM romidepsin (Figure 2D). 
Romidepsin suppresses myofibroblast 
differentiation
TGF-β
1
 is a potent stimulus for myofibroblast 
differentiation that is characterized by induction of α-SMA 
expression. As expected, TGF-β
1
 promoted expression of 
α-SMA in IPF fibroblasts with mRNA expression being 
increased 6-fold by TGF-β
1
. Treatment with romidepsin 
dose-dependently inhibited this effect, with significant 
suppression of myofibroblast differentiation at 5nM 
romidepsin (Figure 3A). Previous studies showed that 
HDAC4 silencing inhibited myofibroblast differentiation 
[14]. Consistent with this, we found that TGF-β
1
 up-
regulated HDAC4 mRNA expression in IPF fibroblasts, 
and this was prevented in the presence of romidepsin 
(Figure 3B). Inhibition of HDAC4 expression was evident 
with doses as low as 0.01nM, while 1nM romidepsin 
abolished the TGF-β
1
-mediated effect. 
A key feature of myofibroblast activity is the ability 
to synthesize ECM components in response to TGF-β
1
. 
Figure 1: Romidepsin dose and time dependently increased acetylation of histone H3: Fibroblasts were cultured 
in DMEM/FBS ± TGF-β
1 
(5ng/ml) with the indicated concentration of romidepsin for 48-144 hours. Cell lysates were 
analysed by SDS-PAGE and western blotting for acetyl- and pan-histone H3. A. Representative western blot with B. semi-quantitative 
analysis of the dose-response of IPF fibroblasts to romidepsin at 48h in the absence (solid bars) and presence (open bars) of TGF-β
1
. C. 
Time-dependent response to 1nM romidepsin ± TGF-β
1
. Data are shown as mean + SD (n = 3; two-way ANOVA with Dunnett’s multiple 
comparisons). *P < 0.05, **P < 0.01, ***P < 0.001. Where there are no lines to indicate the statistical comparison, it is between the starred 
bar and its equivalent baseline non-romidepsin treated control. 
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Figure 2: Inhibition of fibroblast proliferation by romidepsin: IPF and normal fibroblasts were cultured for up to 
144h in DMEM/FBS ± TGF-β
1
 (5ng/ml) and ± romidepsin. Cells were formalin-fixed before being stained with methylene 
blue. Stained cells were eluted with a 1:1 ratio of 0.1% HCl and ethanol. Absorbance was measured at 630nm using a photometric plate 
reader. A. Dose response of IPF fibroblasts to romidepsin at 144h in the absence (solid symbols) or presence (open symbols) of TGF-β
1
. B. 
Comparison of the romidepsin concentration required to achieve 50% growth inhibition (IC
50
) of the IPF and normal fibroblasts at 144h. 
C. At 48h, after culturing as described, RNA was extracted using the Trizol method prior to cDNA synthesis and analysis by RTqPCR. 
Data were normalized to the housekeeping genes UBC/A2 using the ΔΔCT method. CDKN1A mRNA expression in response to increasing 
doses response of romidepsin in IPF fibroblasts without (solid bars) or with (open bars) TGF-β
1
. Data in B. & C. are shown as mean + SD 
(n = 3; two-way ANOVA with Dunnett’s multiple comparisons). *P < 0.05, **P < 0.01. D. Cell cycle analysis of romidepsin treatment of 
3 primary IPF fibroblasts cultures quantitatively determined by propidium iodide (PI)  flow cytometric analysis. Solid bar = G1, grey bar = 
S, open bar = G2/M phase. Data are shown as mean + SD (n = 3; one-way ANOVA). **P < 0.01. Where there are no lines to indicate the 
statistical comparison, it is between the starred bar and its equivalent baseline non-romidepsin treated control.
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When IPF fibroblasts were treated with TGF-β
1, 
a 2.5-fold 
increase in COL3A1 mRNA expression was observed and 
romidepsin dose-dependently blocked this effect (Figure 
3C). COL3A1 mRNA expression in control fibroblasts 
was also inhibited by romidepsin, but the effect was not 
as marked, particularly in response to TGF-β
1
 where there 
was significantly less inhibition compared to the fibrotic 
fibroblasts (Figure 3D).
To further evaluate the effect of romidepsin, we 
modeled fibroblastic foci using 3D pellet cultures as 
described previously [17] and assessed release of soluble 
collagen and α-SMA expression in response to TGF-β
1
. 
After 7 days of culture, TGF-β
1
 significantly increased 
release of soluble collagen into the medium and there 
was an increase in α-SMA immunostaining in the cells. In 
the presence of romidepsin, these effects of TGF-β
1
 were 
reduced (Figure 4A and 4B respectively).
Romidepsin spares ATII cells
ATII cells synthesize and secrete pulmonary 
surfactant and act as progenitor cells in response to lung 
injury by trans-differentiating into ATI cells [37]. In view 
of the potent effects of romidepsin on IPF fibroblasts, 
we assessed the effect of this drug on primary ATII 
cells isolated from human lung tissue. Using a direct 
cell counting assay, ATII cell numbers were unaffected 
by romidepsin even at doses more than 10x the IC
50 
for 
fibroblasts; parallel comparison confirmed the effect 
of romidepsin on IPF fibroblasts in this assay (Figure 
5A). To further assess the effects of romidepsin on 
ATII cell function, we assessed its effects on lamellar 
body formation. Lipid imaging, by coherent anti-Stokes 
Raman scattering spectroscopy (CARS) [38], revealed 
structures comparable in size (1-3μm) to typical ATII cell 
lamellar bodies. These were present in equal numbers 
Figure 3: Romidepsin suppressed myofibroblast differentiation: Fibroblasts were cultured in DMEM/FBS ± TGF-β
1 
with the indicated concentration of romidepsin for 48 hours and then samples harvested into Trizol for RNA isolation, 
cDNA synthesis and RTqPCR analysis. Figure shows mRNA expression of A. ACTA2 B. HDAC4  and C. COL3A1 mRNA in IPF 
fibroblasts in response to romidepsin in the absence (solid bars) or presence (open bars) of TGF-β
1
. D. Inhibition of COL3A1 mRNA 
expression by 5nM romidepsin ± TGF-β
1 
in normal or IPF fibroblasts expressed as a percentage of the corresponding untreated control. 
Data were normalized to the housekeeping genes UBC/A2 using the ΔΔCT method. Data are presented as mean + SD (n = 3; two-way 
ANOVA with Dunnett’s multiple comparisons). *P < 0.05, **P < 0.01. Where there are no lines to indicate the statistical comparison, it is 
between the starred bar and its equivalent baseline non-romidepsin treated control.
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between untreated and treated samples (Figure 5B-5C). 
Lamellar bodies were also detected by TEM showing 
osmiophilic organelles characterized by a multi-lamellar 
structure without any marked difference between treated 
and untreated samples (Figure 5B). Together these data 
suggest that romidepsin has minimal effects on ATII cells 
at doses that markedly suppress fibroblast responses.
Romidepsin suppresses pulmonary fibrosis in vivo
To test the efficacy of romidepsin as an anti-fibrotic 
agent in vivo, we employed the bleomycin-induced model 
of pulmonary fibrosis [39, 40]. Initially, we investigated 
the effect of romidepsin on early changes in gene 
expression associated with development of pulmonary 
fibrosis, using groups of mice treated with a single dose 
of romidepsin (2mg/kg, IP) 3 days after oropharyngeal 
instillation of bleomycin. Four days later, western blotting 
of lung lysates revealed that romidepsin treatment had 
caused a significant increase in H3 acetylation in either 
PBS or bleomycin-exposed mice (Figure 6A). Romidepsin 
also significantly prevented up-regulation of pro-fibrotic 
genes including Fn1 and Col3a1 mRNA in the bleomycin-
exposed mice, whilst a trend for suppression of Col1a1 
was observed (Figure 6B-6D). Since these short-term 
experiments confirmed that romidepsin was having the 
desired effects on histone acetylation and pro-fibrogenic 
gene expression, we next evaluated its effect on lung 
pathology using mice that had received bleomycin and 
were treated with romidepsin or vehicle control on days 
3, 7, 11, and 15, with lungs being harvested on day 
21. Immunohistochemistry using Gomori’s trichrome 
stain showed that under these conditions, romidepsin 
reduced fibrosis caused by bleomycin and preserved lung 
architecture (Figure 7A-7B). Romidepsin also inhibited 
the bleomycin-induced increase in lung wet-weight 
(an indicator of increased tissue density and protein 
accumulation) and collagen content, as assessed by 
hydroxyproline assay (Figure 7C-7D). 
LOX as a biomarker of romidepsin activity
LOX is a secreted enzyme that initiates crosslinking 
of collagens and elastin and is regulated by TGF-β
1 
[24, 
25]. We detected significantly higher levels of LOX 
mRNA in IPF fibroblasts treated with TGF-β
1 
compared 
to control fibroblasts (Figure 8A). This effect of TGF-β
1 
was dose-dependently reduced by romidepsin (Figure 8B). 
As the primary location of LOX is extracellular [41], we 
also evaluated changes at the protein level in fibroblast 
cell-conditioned media. Pro- and active forms of LOX 
were both detectable, with the 32kDa active form being 
predominant under the conditions studied. At 48h, 10nM 
romidepsin significantly suppressed active LOX protein 
expression in IPF fibroblasts, both in the absence or 
presence of TGF-β
1 
(Figure 8C). Romidepsin had a long-
Figure 4: Romidepsin inhibited soluble collagen production and α-SMA expression in 3D pellet culture: 3D pellet 
cultures were treated without or with 5nM romidepsin in the absence or presence of TGF-β
1 
for 144h, at which point 
the pellet was fixed and paraffin embedded. A. assessment of soluble collagen released by the pellets under the indicated conditions 
and B. representative immunohistochemical staining for α-SMA. In A. data are presented as mean + SD (n = 3; one-way ANOVA with 
Dunnett’s multiple comparisons). *P < 0.05. Where there are no lines to indicate the statistical comparison, it is between the starred bar and 
its equivalent baseline non-romidepsin treated control.
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lasting effect, preventing the accumulation of LOX in 
conditioned media from cells treated with TGF-β
1
, up to 
72h after a single drug treatment (Figure 8D). Consistent 
with these in vitro findings, Western blotting of lung 
homogenates from bleomycin treated mice revealed that 
LOX protein was suppressed by romidepsin (Figure 8E), 
suggesting that suppression of LOX protein levels may be 
a biomarker of romidepsin activity in vivo.
To assess whether LOX was increased in IPF lungs, 
BALF was obtained from 9 normal subjects and 20 
subjects with a diagnosis of IPF established by a multi-
disciplinary team according to ATS/ERS/JRS/ALAT 
criteria [6]. Western blotting revealed a major protein band 
at 50kDa, consistent with the presence of pro-LOX (Figure 
9A). This band was detected in all samples and semi-
quantitative analysis revealed significant up-regulation 
in BALF from IPF patients compared to controls (Figure 
9B). Although the age of the control donors was lower 
than the IPF subjects, there was no significant correlation 
between age and pro-LOX expression in the IPF group 
(R2 = 0.07 and P = 0.27). Interestingly, BALF eosinophil 
count correlated closely with pro-LOX densitometry levels 
(Figure 9C). In addition to the presence of pro-LOX, other 
smaller bands between 32-50kDa were detected in some 
samples. These bands most likely represent glycosylated 
forms of active LOX, or partially processed forms of 
the enzyme [41]. Active LOX was minimal in control 
BALF with only 1 of 9 (11%) samples exhibiting strong 
immunoreactivity; in contrast, active LOX was present in 
12 of 20 (60%) IPF BALF samples. Those subjects with 
active LOX also had higher pro-LOX densitometry. 
DISCUSSION
IPF is a fatal disease characterized by uncontrolled 
fibroblast proliferation, myofibroblast differentiation 
and excessive ECM deposition suggesting that multiple 
signaling pathways may be involved in disease 
pathogenesis. Since epigenetic mechanisms have been 
implicated in IPF [10-12] and we have shown that the 
HDAC inhibitor SpA has powerful anti-fibrotic effects 
[17], here we report the potential of romidepsin as a 
candidate therapy for IPF. This anti-cancer agent holds 
great promise and could be readily progressed into an IPF 
Figure 5: Comparison of the effect of romidepsin on alveolar type 2 cells. A. The ATII cells (solid bar), isolated from lung 
resections of 3 different patients, were treated with a range of concentrations of romidepsin, using IPF fibroblasts (open bar) as controls. 
After 72h, cell proliferation was determined by DAPI staining and direct counting of cell nuclei. B. (Upper panel) Coherent anti-Stokes 
Raman spectroscopy of lipids/surfactants in ATII cells alone or after treatment with 5nM romidepsin for 72h. (Lower panel) Transmission 
electron microscopy (TEM) of the ultrastructure of ATII cells cultured on Transwells® for 72h without or with 5nM romidepsin. C. CARS 
image analysis of the pixel ratio of surfactants lipid droplets (LDs) over cell area. In (A & C) data are shown as mean + SD (n = 3 donors; 
two-way ANOVA). * P < 0.05, *** P < 0.001.
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clinical trial, as it is a licensed and established therapy in 
CTCL. 
Romidepsin exhibited potent anti-proliferative 
and anti-fibrotic properties when tested on human IPF 
fibroblasts in vitro without any significant harmful effect 
on ATII cells. Romidepsin also showed anti-fibrotic 
activity in a murine model of pulmonary fibrosis and its 
effects were associated with increased histone acetylation 
consistent with the drug acting as an epigenetic modulator. 
Finally, to further support development of romidepsin as 
a novel therapeutic approach for IPF, we have identified 
LOX as a potential candidate biomarker for a proof-of-
mechanism clinical trial of romidepsin. 
The 2011 ATS/ERS/JRS/ALAT statement on 
IPF [6] highlighted the failure of numerous ‘single 
pathway’ agents to show efficacy in clinical trials of IPF. 
HDACs increase acetylation of histones and non-histone 
proteins, including transcription factors, to regulate 
gene expression. Thus, by targeting multiple genes and 
pathways, HDAC inhibitors offer a novel therapeutic 
strategy to address the unmet need in IPF. Consistent 
with this, our data demonstrate that romidepsin potently 
inhibits multiple fibrogenic processes including fibroblast 
proliferation, myofibroblast differentiation and ECM 
synthesis. Increased expression of p21waf1 leading to 
G1/S cell cycle arrest explains the effect of romidepsin 
on cell proliferation, while suppression of HDAC4 
expression would account for its effect on myofibroblast 
differentiation [14]. Using 2D and 3D culture models, 
as well as an in vivo model of pulmonary fibrosis, 
romidepsin suppressed interstitial collagen production as 
well as expression of LOX, whose activity is required for 
Figure 6: Romidepsin increased histone acetylation and suppressed pro-fibrotic gene expression in bleomycin treated 
mice: Bleomycin (2U/kg) was instilled via the oropharyngeal route to induce lung fibrosis. Romidepsin (2mg/kg IP) or 
a vehicle control was administered 4 days post bleomycin treatment and lungs harvested on day 7 for analysis by western blotting and 
RTqPCR. A. Lungs were homogenized in normal saline with protease inhibitors and lysates analyzed for acetyl histone H3 protein by 
Western blotting using pan histone H3 as the loading control. mRNA expression for B. Fn1, C. Col3a1 and D. Col1a1 analyzed by RTqPCR 
with the gene of interest being normalized to the housekeeping gene Gapdh using the ΔΔCT method. Data are presented as mean + SD (n 
= 4 per group within one experiment; two-way ANOVA with Tukey’s multiple comparisons). **P < 0.01, ***P < 0.001.
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collagen cross-linking. Thus, romidepsin may suppress 
the secretion of collagen and its cross-linking thereby 
reducing the stiffness of the ECM that has been observed 
in IPF lung [42]. This should promote matrix turnover to 
facilitate resolution of aberrant wound healing responses. 
The anti-proliferative effects of romidepsin occurred 
at low nanomolar concentrations, significantly lower 
than those required with other HDAC inhibitors. In our 
in vitro studies, the effects of romidepsin appeared to be 
cytostatic, in line with our previous work on SpA [17] 
and similar work in cancer cells [43]. In contrast with 
its potent effects on fibroblasts, romidepsin had little 
effect on ATII cell number or lamellar bodies, suggesting 
minimal toxicity on this cell type. Lamellar bodies are 
storage organelles of pulmonary surfactant and their 
degeneration has been reported as a marker of toxicity 
and injury for the lung epithelium [44-46]. Our findings 
are consistent with studies of romidepsin in CTCL where 
no pulmonary toxicity was reported [20]. Furthermore, in 
phase II trials in lung cancer, romidepsin shifted the global 
gene expression profile of the cancer cells towards that of 
normal epithelial cells [22]. 
Romidepsin completed phase I trials prior to fast-
track FDA-approval for use in CTCL in 2004, and its dose-
Figure 7: Romidepsin suppressed bleomycin induced pulmonary fibrosis in vivo: Bleomycin was instilled via the 
oropharyngeal route to induce lung fibrosis. Romidepsin (2mg/kg IP) or vehicle control was administered days 3, 7, 11, and 
15 days post bleomycin treatment and the mice were harvested on day 21. A. & B. Representative images of left lung sections stained 
with Gomori’s trichrome stain to visualize collagen (blue). The right lung was weighed C. and then homogenized for determination of 
hydroxyproline content D.. Data are presented as mean + SD (n = 6 per group within two experiments; two-way ANOVA with Tukey’s 
multiple comparisons). *P < 0.05.
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limiting side effects include thrombocytopenia, nausea and 
fatigue [47]. Following from our findings in vitro, it may 
be possible that lower doses of romidepsin will be required 
in an IPF application compared to CTCL as cytostatic, 
rather than cytotoxic, effects are desired. Furthermore, 
in the phase II trial of lung cancer, the maximum steady-
state plasma DP concentrations ranged from 384 to 1,114 
ng/mL [22]. As these doses are more than 2 orders of 
magnitude greater than those required to inhibit growth of 
IPF fibroblasts and ECM biosynthesis by myofibroblasts, 
Figure 8: Inhibition of LOX expression by Romidepsin: IPF or normal fibroblasts were cultured in DMEM/FBS in the 
absence (solid bars) or presence (open bars) of TGF-β
1
 and ± romidepsin for 48h. Cells were lysed for RNA analysis by RT-
qPCR and cell-conditioned media harvested for western blot analysis. A. LOX mRNA expression in the absence or presence of TGF-β
1 
after 
48h. Data are presented as mean + SD (n = 3 per group; one-way ANOVA) B. LOX mRNA expression in IPF fibroblasts with increasing 
concentrations of romidepsin in the presence or absence of TGF-β
1
. Data were normalized to the lowest expressing fibroblast cell line from 
a control donor at baseline. C. & D. Western blot analysis of active LOX protein (32 kDa) secreted from IPF fibroblasts, demonstrating dose 
and time responses, respectively, to romidepsin. Representative blot is shown in panel C; data were normalized to total protein loaded using 
a Ponceau stain and expressed relative to a positive control to control for between blot variation. Data in B.-D. are presented as mean + SD 
(n = 4 IPF donors, each performed in duplicate). E. Semi quantitative analysis of LOX protein measured in homogenized mouse lung as 
prepared as previously described in Figure 7. Data are presented as mean + SD (n = 4 per group within one experiment; two-way ANOVA 
with Tukey’s multiple comparisons). *P < 0.05, **P < 0.01, ***P < 0.001. Where there are no lines to indicate the statistical comparison, 
it is between the starred bar and its equivalent baseline non-romidepsin treated control.
Oncotarget11www.impactjournals.com/oncotarget
it seems likely that lower doses of romidepsin may provide 
an anti-fibrotic effect with much lower associated toxicity.
In taking forward a novel IPF therapeutic into 
clinical development, one of the significant challenges 
is the lack of sensitive clinical end-points resulting in 
large trials of long duration [48]. One way to improve 
confidence in a potential therapeutic is demonstration 
of target engagement (proof of mechanism) in the lung 
by linking preclinical data to clinical readouts. We have 
shown that we can detect elevated levels of pro-LOX, 
in the BALF of IPF patients and that active LOX is 
significantly elevated in patients with a diagnosis of 
IPF. Since romidepsin can reduce LOX expression, our 
studies suggest that a reduction in levels of LOX proteins 
in IPF BALF could provide early evidence of proof-of-
mechanism for romidepsin even before effects on lung 
function or patient survival are evident. We also found an 
interesting correlation between LOX and the number of 
eosinophils detected in the BALF of IPF patients. Previous 
studies have implicated eosinophils in lung fibrosis due to 
their effect on fibroblast proliferation and differentiation 
via TGF-β
1
 [49, 50]. Therefore, it might also be of interest 
to monitor eosinophil numbers following romidepsin 
treatment.
In summary, the potent anti-proliferative and anti-
fibrotic properties of romidepsin in vitro and in vivo 
strongly support progression of this FDA-approved 
HDAC inhibitor towards a clinical trial to evaluate its 
potential as a new therapy for IPF. Identification of LOX 
as secreted protein whose levels are increased in IPF lung 
and whose production is modulated by romidepsin support 
its evaluation as a companion biomarker with the actual 
physiological end-points for assessing the early proof-of-
mechanism of romidepsin in study patients. 
MATERIALS AND METHODS
Compounds
Romidepsin (FK228) was from Selleck Chemicals 
(Munich, Germany) or Celgene Corporation, Summit, 
NJ (ISTODAX®, Romidepsin for injection). Solid was 
dissolved in dimethylsulphoxide (DMSO) (Sigma-Aldrich, 
Gillingham, UK) and then further diluted into aqueous 
solution for use. A vehicle control (DMSO or saline, as 
appropriate) was run in each experiment.
Figure 9: LOX was increased in IPF and correlated with increased eosinophils: BALF from IPF patients and control 
donors were analyzed by western blot for LOX expression. A. Representative blot with B. semi-quantitative analysis of Pro LOX 
expression normalized to Ponceau stain for total protein, and expressed relative to a positive control. C. Regression analysis showing the 
correlation between BAL eosinophils and relative levels of Pro-LOX. Data are presented as mean + SD (n = 9 control and 20 IPF donors). 
**P < 0.01.
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Primary fibroblast culture
Parenchymal lung fibroblast cultures were 
established from explant tissue of patients with IPF 
obtained by video-assisted thoracoscopic lung biopsy 
at University Hospital Southampton (n = 3) or from 
macroscopically normal resected lung tissue (n = 3) 
following ethical approval (LREC: 07/H0607/73 and 
LREC: 08/H0502/32) and informed written consent. 
This work has been carried out in accordance with 
the Declaration of Helsinki. Fibroblasts were cultured 
Table 1: Patient characteristics of control donors and IPF patients used in BALF analysis. 
Controls Age Sex Smoking Hx % FEV
1
% FVC % TLCO
Donor 1 51 F Y 83.8 103.5 83.0
Donor 2 47 M N 108.2 110.7 83.0
Donor 3 65 M N 91.4 97.3 87.0
Donor 4 37 M N 110.5 97.5 90.0
Donor 5 62 M Y 97.1 115.6 109.0
Donor 6 51 F Y 92.2 106.1 70.0
Donor 7 53 M Y 128.1 144.7 75.0
Donor 8 46 N/A N N/A N/A N/A
Donor 9 39 M N 90.9 94.7 76.1
Mean 50.1 6/2/1a 5/4b 100.3 108.8 84.14
SE 3.1 5.1 5.7 4.2
IPF patients Age Sex Smoking Hx % FEV
1
% FVC % TLCO
IPF 1 54 M Y 79.0 73.1 69.0
IPF 2 59 M N 67.4 79.0 38.2
IPF 3 76 F N 86.3 92.8 53.0
IPF 4 65 M N 72.2 65.4 38.7
IPF 5 64 M Y 75.0 74.7 39.4
IPF 6 60 M  N/A 74.7 71.4 28.5
IPF 7 72 F N 123.6 120.5 57.1
IPF 8 73 M N 64.0 56.0 40.0
IPF 9 46 M N 63.0 59.0 30.0
IPF 10 49 M  Ex 57.6 52.7 42.9
IPF 11 58 M  Ex 54.5 49.3 37.0
IPF 12 70 M N 72.1 65.9 50.5
IPF 13 70 M N 83.4 84.2 39.3
IPF 14 74 M  N/A 80.8 77.1 32.4
IPF 15 70 M Y 76.9 74.9 36.4
IPF 16 71 M N 82.2 85.9 54.4
IPF 17 74 M  Ex 78.7 79.7 32.9
IPF 18 66 M  Ex 65.1 62.0 56.1
IPF 19 61 M  Ex 73.9 68.8 30.6
IPF 20 54 M Y 70.6 82.0 73.5
Mean 64.3  18/2a  9/4/5b 75.1 73.7 44
SE 2 3.2 3.6 2.9
a= Male/Female/Not available, b=Never/Yes/Ex smoker. Smoking Hx = smoking history. N/A = not available. % FEV
1
 = forced 
expiratory volume in one second expressed as % predicted, %FVC = forced vital capacity expressed as % predicted, %T
LCO
 
= transfer factor of the lung for carbon monoxide expressed as % predicted. SE = standard error.
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in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% foetal bovine serum (FBS), 
50 units/ml penicillin, 50μg/ml streptomycin, 2mM 
L-glutamine, 1mM sodium pyruvate and 1x non-essential 
amino acids (DMEM/FBS) (all from Life Technologies, 
Paisley, UK). 3D cultures were performed as previously 
described [17]. 
Primary alveolar type II (ATII) cell culture
ATII cells were isolated from macroscopically 
normal regions of surgically resected lung tissue 
obtained with ethical approval (LREC: 08/H0502/32) 
and informed written consent. This work has been carried 
out in accordance with the Declaration of Helsinki. The 
parenchymal lung tissue was processed according to the 
method of Witherden et al. [51]. Briefly, the lung tissue 
was perfused with 0.9% saline solution and instilled with 
0.25% Trypsin (Sigma Aldrich, Poole, UK) at 37°C for 
45 min. After trypsin digestion, the tissues were finely 
sliced in the presence of newborn calf serum (NCS) 
and DNase (250mg/ml), and then cells were filtered by 
sequential passage through a 400μm metal mesh and 
40μm nylon filter. The cells were re-suspended in DCCM-
1 medium (Biological Industries Ltd, Kibbutz Beit-
Haemek, Israel) supplemented with 1% penicillin, 1% 
streptomycin and 1% L-glutamine, and incubated at 37°C 
in a humidified incubator for 2h in tissue culture flasks to 
allow differential adherence and removal of contaminating 
mononuclear cells. The alveolar epithelial cells were re-
suspended in fresh DCCM-1 supplemented with 10% 
NCS, 1% penicillin, 1%streptomycin and 1% L-glutamine 
and plated on collagen 1 (PureCol 5005-b, Advanced 
BioMatrix Inc., California USA) coated 96 well plates at 
60% density; after 72h purity was tested by staining for 
alkaline phosphatase.
Methylene blue proliferation assay
Fibroblasts (1x103 cells/well in DMEM/FBS) were 
treated in the absence or presence of 5ng/ml TGF-β
1
 
(PeproTech, London, UK) for 24h prior to treatment 
with romidepsin. TGF-β
1 
5ng/ml had previously 
been determined (unpublished data) as the optimum 
concentration to induce myofibroblast differentiation, a 
key event in fibrosis. Cells were fixed in formal saline 
at 48, 72 and 144h before staining with methylene blue 
[52]. Cell number, determined by direct cell counting, was 
proportional to absorbance at 630nm after stained cells 
were eluted in 100μl 1:1 0.1% HCl and ethanol. 
Cell proliferation by direct cell counting
Human ATII cells (n = 3, 1 male and 2 female) 
and IPF fibroblasts (n = 3, 3 male) were plated at 60-
70% confluence and then treated and then treated with 
romidepsin. After 72h, the cells were fixed in 90% ethanol 
and nuclei stained with 4’,6-diamidino-2-phenylindole 
(DAPI). Cell nuclei were imaged by tile scan fluorescent 
microscopy of the entire well and counted using ImageJ 
software.
Reverse transcription and quantitative PCR 
(RTqPCR)
Fibroblasts (1x105/well in DMEM/FBS) were 
pre-treated with medium alone, or with 5 or 10ng/ml 
TGF-β
1
 for 24h prior to treatment with Romidepsin. At 
48h, RNA was isolated using Trizol (Life Technologies, 
Paisley, UK) and any genomic DNA contamination 
removed by DNase treatment (Ambion, Warrington, 
UK) before cDNA synthesis. Changes in mRNA 
expression using the following primers were analyzed 
by qPCR and normalized to the housekeeping genes 
ubiquitin C and phospholipase A2 (UBC and A2) using 
the ∆∆CT method [53]: CDKN1A (NM_000389), 
Fwd 5’-TCCAGCCGACCTTCCTCATC-3’ 
and Rev 5’-GCCTCTACTGCCACCATCT-3’; 
ACTA2 (NM_001613), Fwd 
5’-AAGCACAGAGCAAAAGAGGAAT-3’ 
and Rev 5’-ATGTCGTCCCAGTTGGTGAT-3’; 
HDAC4 (NM_006037), Fwd 
5’-GCCACCATTCACCTCTGTAAT-3’ and Rev 
5’-AAATCCACCCACACAAAACAAG’-3; 
COL1A1 (NM_000088), Fwd 
5’-AGACAGTGATTGAATACAAAACCA-3’ and Rev 
5’-GGAGTTTACAGGAAGCAGACA-3’; COL3A1 
(NM_000090), Fwd 5’-GTCCCGCTGGCATTCCTG-3’ 
and Rev 5’-CTCTCCTTTGGCACCATTCTTAC-3’ 
LOX (NM_002317), Fwd 
5’-GATATAGTCTAAATTAGCAAAGCACATAG-3’ and 
Rev 5’-ATTACGCAGCACAGTCCTTG-3’ . For murine 
fibrosis studies, left lungs were collected into RNA later®. 
For RNA extraction, the lungs were transferred into 
Trizol reagent homogenized using a Ribolyser (Savant 
FastPrep FP12, Qbiogene Cedex, France) and then RNA 
extracted as above. Changes in mRNA expression were 
analyzed using the following primers: Fn1 (NM_010233), 
Fwd 5’-AAGAGGACGTTGCAGAGCTA-3’ and Rev 
5’- AGACACTGGAGACACTGACTAA; Col3a1 
(NM_009929), Fwd  5’-CCGTTGAGTCCGTCTTTGC-3’ 
and Rev 5’-ATATGCCCACAGCCTTCTAC-3’; 
Col1a1 (NM_007742), Fwd  5’-
GTCCACGTAGTTGGCGACTTC-3’ and Rev 
5’-CCGTTGAGTCCGTCTTTGC-3’; Lox (NM_010728) 
Fwd 5’-GACATTCGCTACACAGGACAT-3’ and Rev 
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5’-AACACCAGGTACGGCTTTATC-3’. Data were 
normalized to the housekeeping gene Gapdh using the 
∆∆CT method [53]. All PCR reagents (including reverse 
transcription kits) were purchased from PrimerDesign Ltd 
(Southampton, UK).
Soluble collagen expression (sircol assay)
Briefly, fibroblasts were pelleted at 1x106/ml and 
placed in 2ml DMEM/FBS in the absence or presence 
of 5ng/ml TGF-β
1
 and without or with 5nM romidepsin. 
Supernatants were exchanged every second day and 
harvested conditioned media clarified by centrifugation 
for analysis of soluble collagen. Soluble collagen was 
measured in cell-free culture supernatants using the sircol 
assay according to the manufacturer’s instructions (Sircol 
Collagen Assay Kit; Biocolor Ltd, Carrickfergus, UK). 
Briefly, culture medium was treated with an isolation 
and concentration reagent overnight on an ice-water 
mix at 4°C. Samples were centrifuged at 12,000rpm 
for 10 minutes at 4°C and the supernatant removed. 
Sirius red dye was added to the pellet to form a complex 
with the collagen. Unbound dye was removed and the 
pellet solubilized in alkali reagent for measurement of 
absorbance at 555nm to allow quantification by a reference 
standard curve.
Western blot analyses
Fibroblasts were cultured as for RNA analysis. 
After incubation, cells were lysed into SDS sample buffer 
for SDS-PAGE and cell conditioned media clarified by 
centrifugation before concentrating secreted proteins 
using StrataClean resin at 1:10 (Agilent Technologies, 
Wokingham, UK) [54]. For murine fibrosis studies, right 
lungs were snap frozen and then homogenized in normal 
saline containing protease inhibitors (Roche, Burgess Hill, 
UK) before solubilization in SDS sample buffer for SDS-
PAGE.
Western blotting of cellular or lung lysates was 
performed for acetyl histone H3, 1:20000 (Merck 
Millipore, Watford, UK), and of cell-conditioned medium 
for secreted pro-LOX and LOX, (1:20, Sigma-Aldrich, 
Poole, UK) using enhanced chemiluminescence detection 
(ECL+, GE Healthcare, Buckinghamshire, UK). In the 
case of acetyl H3, membranes were stripped and reprobed 
using pan histone H3 antibodies (Merck Millipore, 
Watford, UK); for LOX quantitation, image analysis 
of Ponceau Red stain (Sigma-Aldrich, Poole, UK) was 
used a loading control. Densitometry was used for semi-
quantitative analysis of the data.
Flow cytometry analysis
Cell cycle was quantitatively determined by flow 
cytometry analysis. Fibroblasts (1x103cells/well in 
DMEM/FBS) were cultured for 48 hours and then treated 
with romidepsin. Cells were collected after 48h treatment 
and fixed in cold (-20°C) 70% ethanol, treated with RNase 
A 42μg/ml, and stained with 7μg/ml of PI. A FACS Calibur 
(Becton Dickinson) was used to quantify the percentage 
of cells in each cell cycle phase by acquiring 10,000 
events per sample. Analysis of cell cycle distribution was 
performed with BD CellQuest software.
CARS microscopy
ATII cells were plated at 60% density on collagen 
I coated multi-well chamber slides (Grace Bio-Labs, 
Stratech Scientific Limited, Newmarket, UK) for high-
resolution imaging. After attachment, the cells were 
treated with 5nM romidepsin and the cells were cultured 
for 72h before fixation in 4% paraformaldehyde (PFA). A 
purpose-built CARS microscope comprising a Chameleon 
(Coherent) and Compact OPO (APE Berlin) coupled to an 
inverted Nikon Ti-U 2000 microscope (Nikon, Kingston 
upon Thames, UK) was used to acquire images. Images 
were acquired with a 40x (NA: 1.2) water-immersion 
objective (Nikon). Symmetric CH2 vibrations at the 
Raman vibrational frequency of 2845 cm-1 were used to 
selectively image surfactant lipid droplets (LDs) in the 
cells [55]. Images (n = 7-11) were acquired on random cell 
areas for each condition. LDs were quantified using a code 
written in MATLAB (MathWorks, Cambridge, UK). The 
number of pixels with intensities exceeding the threshold 
were counted and were compared with the overall cell area 
in pixels to obtain a ratio of LDs per cell area. 
Transmission electron microscopy
Human primary alveolar type II cells were plated 
on porous filter inserts (pore size 0.4μm; Corning 3470, 
Fisher Scientific UK Ltd, Loughborough, UK) coated 
with collagen I and treated with romidepsin 5nM. After 
72h, cells were fixed using 3% glutaraldehyde and 4% 
formaldehyde in 0.1M PIPES buffer pH 7.2, post fixed 
with 1% osmium tetroxide in 0.1M PIPES buffer pH 7.2 
and then with 2% aqueous uranyl acetate. The samples 
were dehydrated in graded ethanols and embedded in 
SPURR resin. Ultrathin sections were obtained using an 
ultra-microtome (Reichert OMu3 Ultra, Type 700141, 
Leica, Milton Keynes, UK) and grids were stained with 
Reynolds lead reagent. Micrograph pictures were acquired 
using transmission electron microscopy (Hitachi H7000, 
Maidenhead, UK).
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Collection and processing of bronchoalveolar 
lavage fluid (BALF)
BALF was collected by fiberoptic bronchoscopy 
performed according to current guidelines [56]. BALF 
from IPF patients was collected at the Royal Brompton 
Hospital, London (n = 20, LREC:10/H0720/12) and 
healthy volunteers at the NIHR Respiratory Biomedical 
Research Unit, Southampton University Hospitals NHS 
Trust (n = 9, LREC:09/H0502/91). All patients met the 
ATS/ERS/JRS/ALAT criteria for the diagnosis of IPF 
[6]; subject characteristics are given in Table 1. Samples 
of BALF containing 20μg protein were processed using 
Strataclean resin and the eluted protein analyzed for LOX 
protein by western blotting, as described above.
Bleomycin mouse model
All animal procedures were performed in 
compliance with the US Department of Health and 
Human Services Guide for the Care and Use of Laboratory 
Animals. The study was approved and supervised by the 
University of Rochester University Committee on Animal 
Resources. Adult male C57BL/6J mice (The Jackson 
Laboratory, Bar Harbor, ME) were treated, at 8 weeks 
of age, with 2U/kg pharmaceutical grade bleomycin 
(Hospira, Lake Forest, IL) in 40µl PBS by oropharyngeal 
aspiration [57], or PBS alone (controls). Mice were 
group housed in shoebox cages (3-5 mice per cage) on 
a 12 hours light/dark cycle and received food and water 
ad libitum; mice were randomly assigned to treatment 
groups. The dose of romidepsin (2mg/kg IP in saline) used 
for the study was based on previous cancer studies in mice 
[58]. To assess early gene expression changes associated 
with fibrosis, mice were injected with a single dose of 
romidepsin (2mg/kg IP in saline) or saline alone (control) 
on day 3 after bleomycin and harvested on day 7. The left 
lung was snap frozen for later Western blot analysis and 
the right lung was stored in RNAlater® (Qiagen, Valencia, 
CA) for later determination of mRNA levels. To assess 
the effect of romidepsin on fibrosis, mice were treated 
with bleomycin as described, and treated with romidepsin 
(2mg/kg IP) on days 3, 7, 11, and 15; and harvested on 
day 21. The right lung was dissected away from the left 
lung and other tissue, the wet weight was determined, 
and the lung was then used for hydroxyproline assay as 
described [57]. The left lung was inflated and fixed with 
neutral buffered formalin. Sections (5µm) were stained 
with Gomori’s Trichrome, and whole slide images were 
taken with an Olympus WS110 whole slide imager. 
Statistical analysis
Differences between two means were assessed 
using either Students T test or Mann-Whitney U test 
for parametric or non-parametric data respectively. For 
multiple comparisons, analysis of variance (ANOVA) was 
employed with a Tukey or Dunnett’s post-test. p < 0.05 
were accepted as statistically significant. *p < 0.05, **p < 
0.01, *** p < 0.001.
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